Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04594798 · ClinicalTrials.gov registry record · Phase 2
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
A Phase 2 study of Lymphoma, B-Cell and DLBCL, sponsored by University of Rochester.
- Active
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT04594798 is a Phase 2 study of Lymphoma, B-Cell and DLBCL that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 39 participants, below the 200-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04594798, a Phase 2 study of Lymphoma, B-Cell and DLBCL, is active but no longer recruiting, sponsored by University of Rochester.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Prednisone
- DRUG Polatuzumab vedotin
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04594798
The ClinicalTrials.gov registry entry for NCT04594798 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 200-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target (80% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma, B-Cell appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04594798 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04594798 about?
NCT04594798 is a clinical study titled "A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL". The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
What is the current status of trial NCT04594798?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2021-09-20. Estimated completion is 2026-07-31.
What conditions does trial NCT04594798 study?
This clinical trial studies the following conditions: Lymphoma, B-Cell, DLBCL.
What interventions are being tested in trial NCT04594798?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Prednisone (DRUG), Polatuzumab vedotin (DRUG).
Who is sponsoring clinical trial NCT04594798?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04594798 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, B-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
RECRUITING · Phase 2
-
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
COMPLETED · Phase 2
-
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
COMPLETED · Phase 2
-
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
COMPLETED · Phase 2
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.